InnoCare Pharma Company Profile - aVenture Research
InnoCare Pharma
InnoCare Pharma is a commercial-stage biopharmaceutical company developing therapies for cancer and autoimmune diseases, listed in Hong Kong and Shanghai.
InnoCare Pharma is a commercial-stage biopharmaceutical company founded in Beijing in 2015 by Jasmine Cui and Yigong Shi. Dual-listed on the Hong Kong Stock Exchange and the Shanghai STAR Market, it has grown into a commercial organization with three marketed drugs. It listed in Hong Kong in 2020 and on Shanghai's STAR Market in 2022.
Its pipeline spans more than ten clinical programs across BTK, TYK2-JH1 and JH2, and bispecific antibody platforms. Late-stage TYK2 candidates soficitinib (ICP-332) and fadeucravacitinib (ICP-488) anchor its autoimmune portfolio alongside oncology programs. The company pursues first-in-class or best-in-class molecules for large cancer and autoimmune patient populations.